{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adult+CML&page=2", "query": { "condition": "Adult CML", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adult+CML&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T10:12:00.417Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00964821", "title": "Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Nonmalignant Neoplasm" ], "interventions": [ { "name": "trivalent influenza vaccine", "type": "BIOLOGICAL" }, { "name": "Immunoenzyme technique", "type": "OTHER" }, { "name": "Laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 459, "start_date": "2007-01", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2017-11-07", "last_synced_at": "2026-07-24T10:12:00.417Z", "location_count": 2, "location_summary": "Duarte, California • Pasadena, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00964821" }, { "nct_id": "NCT00726830", "title": "Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Pain", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "methadone hydrochloride", "type": "DRUG" }, { "name": "morphine sulfate", "type": "DRUG" }, { "name": "oxycodone hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2009-03", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-07-24T10:12:00.417Z", "location_count": 2, "location_summary": "Spartanburg, South Carolina • Houston, Texas", "locations": [ { "city": "Spartanburg", "state": "South Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00726830" }, { "nct_id": "NCT00036738", "title": "Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia in Remission", "Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Blastic Phase", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Phase of Disease", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Disease" ], "interventions": [ { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Therapeutic Allogeneic Lymphocytes", "type": "BIOLOGICAL" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 28, "start_date": "2001-07-13", "completion_date": "2018-05", "has_results": true, "last_update_posted_date": "2020-01-29", "last_synced_at": "2026-07-24T10:12:00.417Z", "location_count": 3, "location_summary": "Denver, Colorado • Seattle, Washington", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036738" }, { "nct_id": "NCT03326921", "title": "HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Juvenile Myelomonocytic Leukemia", "Recurrent Acute Biphenotypic Leukemia", "Recurrent Acute Undifferentiated Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory Adult Acute Lymphoblastic Leukemia", "Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive", "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm", "Recurrent Myelodysplastic Syndrome", "Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm", "Refractory Myelodysplastic Syndrome", "Acute Undifferentiated Leukemia", "Mixed Phenotype Acute Leukemia", "Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive", "Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Myelodysplastic Syndrome", "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Acute Biphenotypic Leukemia", "Chronic Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Minimal Residual Disease", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Mixed Phenotype Acute Leukemia", "Leukemia", "Chronic Myeloid Leukemia, BCR-ABL1 Positive" ], "interventions": [ { "name": "CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "80 Years", "sex": "ALL", "summary": "Up to 80 Years" }, "enrollment_count": 24, "start_date": "2018-02-23", "completion_date": "2028-07-16", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-07-24T10:12:00.417Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03326921" }, { "nct_id": "NCT00290628", "title": "Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Diamond-blackfan Anemia", "Fanconi Anemia", "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "radiation therapy", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "45 Years", "sex": "ALL", "summary": "Up to 45 Years" }, "enrollment_count": 43, "start_date": "1999-10", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-07-24T10:12:00.417Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00290628" }, { "nct_id": "NCT01159067", "title": "Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Iron Overload", "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Disseminated Neuroblastoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Poor Prognosis Metastatic Gestational Trophoblastic Tumor", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Neuroblastoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Splenic Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage II Ovarian Epithelial Cancer", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Ovarian Epithelial Cancer", "Stage III Small Lymphocytic Lymphoma", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Breast Cancer", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Ovarian Epithelial Cancer", "Stage IV Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "deferasirox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2010-07", "completion_date": "2011-08-09", "has_results": true, "last_update_posted_date": "2019-06-18", "last_synced_at": "2026-07-24T10:12:00.417Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01159067" }, { "nct_id": "NCT03884829", "title": "A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML, Adult", "Myelodysplastic Syndromes", "ALL, Adult", "CML, Refractory", "CLL, Refractory" ], "interventions": [ { "name": "CYC140", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cyclacel Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2019-03-25", "completion_date": "2023-10-19", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-07-24T10:12:00.417Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03884829" }, { "nct_id": "NCT06297161", "title": "A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Leukemia Myelogenous" ], "interventions": [ { "name": "Bosulif", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": null, "sex": "ALL", "summary": "20 Years and older" }, "enrollment_count": 600, "start_date": "2025-01-20", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-07-24T10:12:00.417Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06297161" }, { "nct_id": "NCT00383474", "title": "Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia", "Adult Acute Monoblastic Leukemia", "Adult Acute Monocytic Leukemia", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With Maturation", "Adult Acute Myeloid Leukemia With Minimal Differentiation", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL", "Adult Acute Myeloid Leukemia Without Maturation", "Adult Acute Myelomonocytic Leukemia", "Adult Erythroleukemia", "Adult Pure Erythroid Leukemia", "Blastic Phase", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Disease", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Tipifarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2006-08", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2015-04-15", "last_synced_at": "2026-07-24T10:12:00.417Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00383474" }, { "nct_id": "NCT00611351", "title": "Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Secondary Myelofibrosis" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "19 Years to 65 Years" }, "enrollment_count": 5, "start_date": "2005-06-07", "completion_date": "2008-09-17", "has_results": true, "last_update_posted_date": "2023-10-23", "last_synced_at": "2026-07-24T10:12:00.417Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00611351" } ] }